Welcome to our dedicated page for Wearable Devices Ltd. SEC filings (Ticker: WLDS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wearable Devices Ltd. filings document its foreign private issuer reporting for AI-powered touchless sensing wearables, Mudra neural input products and software platforms for XR, mobile and AI applications. Form 6-K reports furnish product announcements, patent notices, financial results and updates on ai6 Labs, Mudra Experience Studio, Mudra Link and Mudra Band.
The filings also cover capital-structure and governance matters, including ordinary shares and tradable warrants, reverse share split disclosure, shareholder meeting results, compensation policy amendments, equity incentive plan share reserves, and incorporation by reference into Form S-8 and Form F-3 registration statements.
Wearable Devices Ltd. filed a post-effective amendment to end two prior Form F-1 resale registrations tied to warrant financings completed in 2024 and 2025. The first registration covered up to 205,500 ordinary shares underlying November 2024 warrants, and the second covered up to 625,000 ordinary shares underlying January 2025 warrants, both for a single investor.
The company states that the selling shareholder has sold all ordinary shares underlying both the November and January warrants and that its contractual obligation to keep each registration statement effective has expired. As a result, Wearable Devices is terminating the related offerings and deregistering any ordinary shares that may remain unsold under those registration statements.
Wearable Devices Ltd. filed a post-effective amendment to close out two previously effective Form F-1 resale registration statements and deregister any remaining unsold ordinary shares. These earlier filings covered the resale of up to 205,500 ordinary shares underlying November 2024 warrants and up to 625,000 ordinary shares underlying January 2025 warrants issued to a single investor in prior financing transactions. The company’s contractual obligation to keep each registration statement effective has expired because the selling shareholder has sold all the warrant shares or can sell them under Rule 144. Wearable Devices has now terminated the related offerings and amended the registration statements to remove from registration any ordinary shares that may still be unsold and to terminate the effectiveness of both registration statements.
Wearable Devices Ltd. has filed a post-effective amendment to its Form F-3 registration statement to deregister any remaining unsold ordinary shares that were previously registered for resale. The original F-3 covered up to 1,661,000 ordinary shares underlying warrants issued under an April 29, 2025 inducement agreement, where an investor exercised existing warrants and received 1,661,000 new warrants at an exercise price of $1.45 per share.
The company had agreed to keep the resale registration effective until three years after effectiveness or until all warrant shares were sold or freely tradable under Rule 144. That commitment has now expired because the selling shareholder has sold all the ordinary shares underlying the April warrants, so the company has terminated the related offering and is formally removing any remaining registered but unsold shares.
Wearable Devices Ltd. is calling a special shareholder meeting on February 19, 2026 to vote on several financing, compensation and capital-structure actions. Shareholders are asked to approve private placements of new warrants, including Ordinary Warrants and amended existing warrants tied to a prior registered direct offering, and a separate inducement grant of New Warrants that could represent 29.1% of fully diluted share capital if exercised. The Board also seeks approval of an amended executive and director compensation policy that raises caps on CEO salary, bonuses and equity awards, plus new RSU grants for the CEO, Chief Scientific Officer/President, and non-executive directors. In addition, shareholders are asked to authorize one or more reverse share splits of up to 3:1 at the Board’s discretion to support continued Nasdaq listing. The Board unanimously recommends voting in favor of all proposals.
Wearable Devices Ltd. has filed an amended prospectus covering the resale of up to 1,670,000 ordinary shares by a single selling shareholder. These shares are issuable from warrants originally sold in September 2025 private placements, with exercise prices currently $4.00 and $6.00 per share that may be reduced to $2.67 per share subject to shareholder approval. The company will receive cash only if the warrants are exercised, which could total about $4.46 million at the reduced price, and plans to use any such proceeds for working capital and general corporate purposes. As of December 16, 2025, 8,648,406 ordinary shares were outstanding, so full exercise of the registered warrants would lift that figure to 10,318,406 shares. The filing also describes additional outstanding warrants, options, RSUs and planned inducement warrants that, if exercised or issued, could substantially increase the share count and dilute existing holders.
Wearable Devices Ltd. reports that it received approval for a $750,000 budget to conduct a neurorehabilitation pilot with Soroka Medical Center. This reflects a funded pilot project focused on neurorehabilitation applications.
The report mainly furnishes a press release about this approval as an exhibit and makes the first two paragraphs and the forward-looking statements section part of several existing Form S-8 and Form F-3 registration statements, so that these disclosures are now formally included in those previously filed share registration documents.
Wearable Devices Ltd. (WLDS) launched a registered direct offering of 655,000 Ordinary Shares and Pre-Funded Warrants to purchase up to 575,000 shares. The Pre-Funded Warrants carry a $0.0001 exercise price and a 9.99% beneficial ownership cap. The combined purchase price is $2.67 per share and $2.6699 per pre-funded unit.
The company estimates net proceeds of approximately $2.9 million for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as financial advisor; the fee table shows $3,284,042 in gross offering price, $262,723 in advisor fees, and $3,021,319 in proceeds before expenses.
In a concurrent private placement (not part of this prospectus), the same investor will receive 1,230,000 unregistered Warrants exercisable at $2.67 per share, effective upon shareholder approval, expiring five years after approval. Ordinary Shares outstanding were 5,960,770 as of October 29, 2025; Ordinary Shares to be outstanding after this offering are 6,615,770.
Wearable Devices Ltd. (WLDS) entered a Securities Purchase Agreement for a registered direct offering to a single institutional investor, selling 655,000 ordinary shares at $2.67 per share and pre‑funded warrants for up to 575,000 shares at $2.6699 each, each with an accompanying ordinary warrant.
The Pre‑Funded Warrants are exercisable immediately at $0.0001 per share and include a 9.99% beneficial ownership cap. In a concurrent private placement, the Company will issue ordinary warrants for up to 1,230,000 shares with a $2.67 exercise price, exercisable upon shareholder approval and expiring five years after approval. The transaction uses an effective Form F‑3 and an October 29, 2025 prospectus supplement.
The Company agreed to 60‑day restrictions on additional issuances and variable‑rate transactions, subject to specified exceptions. Existing September 2025 investor warrants for 1,000,000 shares at $4.00 and 670,000 shares at $6.00 will have their exercise prices reduced to $2.67, subject to shareholder approval, and will expire five years after approval.